GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Price-to-Free-Cash-Flow

EVAX (Evaxion Biotech AS) Price-to-Free-Cash-Flow : N/A (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Price-to-Free-Cash-Flow?

As of today (2024-12-11), Evaxion Biotech AS's share price is $1.30. Evaxion Biotech AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, Evaxion Biotech AS's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Evaxion Biotech AS's Price-to-Free-Cash-Flow or its related term are showing as below:

EVAX's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 36.58
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Evaxion Biotech AS's Free Cash Flow per Share for the three months ended in Sep. 2024 was $0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 6.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -44.40% per year.

During the past 7 years, Evaxion Biotech AS's highest 3-Year average Free Cash Flow per Share Growth Rate was 6.40% per year. The lowest was -125.60% per year. And the median was -44.00% per year.


Evaxion Biotech AS Price-to-Free-Cash-Flow Historical Data

The historical data trend for Evaxion Biotech AS's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evaxion Biotech AS Price-to-Free-Cash-Flow Chart

Evaxion Biotech AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Evaxion Biotech AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evaxion Biotech AS's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Evaxion Biotech AS's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion Biotech AS's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Price-to-Free-Cash-Flow falls into.



Evaxion Biotech AS Price-to-Free-Cash-Flow Calculation

Evaxion Biotech AS's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.30/0
=N/A

Evaxion Biotech AS's Share Price of today is $1.30.
Evaxion Biotech AS's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Evaxion Biotech AS  (NAS:EVAX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Evaxion Biotech AS Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Evaxion Biotech AS Business Description

Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.